Who Optimizes SG&A Costs Better? Catalent, Inc. or Axsome Therapeutics, Inc.

Catalent vs. Axsome: SG&A Cost Management Showdown

__timestampAxsome Therapeutics, Inc.Catalent, Inc.
Wednesday, January 1, 20141392830334800000
Thursday, January 1, 20152419289337300000
Friday, January 1, 20166343648358100000
Sunday, January 1, 20177206691402600000
Monday, January 1, 20189351522462600000
Tuesday, January 1, 201913598030512000000
Wednesday, January 1, 202028896749577900000
Friday, January 1, 202166646205687000000
Saturday, January 1, 2022159253661844000000
Sunday, January 1, 2023323123000831000000
Monday, January 1, 2024411359000935000000
Loading chart...

Cracking the code

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Catalent, Inc. and Axsome Therapeutics, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Catalent consistently maintained higher SG&A expenses, peaking at approximately $935 million in 2024. In contrast, Axsome's expenses surged from a modest $1.4 million in 2014 to $323 million in 2023, reflecting its rapid growth trajectory.

Catalent's expenses grew by about 180% over the decade, while Axsome's skyrocketed by over 23,000%, highlighting its aggressive expansion strategy. However, the absence of 2024 data for Axsome suggests a potential gap in reporting or a strategic shift. This comparison underscores the diverse approaches companies take in managing operational costs, with Catalent focusing on steady growth and Axsome on rapid scaling.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025